Company Overview - Henry Schein (HSIC) shares have increased by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Henry Schein have trended upward in the past month, indicating positive sentiment among analysts [2][4] - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Henry Schein has a Growth Score of B and a Momentum Score of B, with an overall VGM Score of A, placing it in the top quintile for investment strategies [3] Industry Performance - Henry Schein is part of the Zacks Medical - Dental Supplies industry, where Becton Dickinson (BDX) has seen a 3.3% increase in the past month [5] - Becton Dickinson reported revenues of $5.27 billion for the last quarter, reflecting a year-over-year growth of 4.5% [5] - For the current quarter, Becton Dickinson is expected to report earnings of $3.45 per share, a decrease of 1.4% from the previous year [6]

Company Performance - McKesson (MCK) has returned approximately 26.6% since the beginning of the calendar year, outperforming the Medical sector, which has lost about 4.9% on average [4] - McKesson holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 1.4% over the past quarter [3] - McKesson belongs to the Medical - Dental Supplies industry, which includes 14 companies and currently ranks 84 in the Zacks Industry Rank, with this group having lost about 1.9% year-to-date [5] Industry Comparison - The Medical sector consists of 999 individual stocks and currently holds a Zacks Sector Rank of 4, which is based on the average Zacks Rank of the individual stocks within the sector [2] - Another stock in the Medical sector, Adagene Inc. Sponsored ADR (ADAG), has a year-to-date return of 4.8% and also holds a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 7.9% over the past three months [4][5] - The Medical - Biomedical and Genetics industry, which includes Adagene, has 503 stocks and is ranked 75, with this industry having moved -2.9% since the beginning of the year [6]

Core Viewpoint - Dentsply International (XRAY) is experiencing solid improvements in earnings estimates, which may lead to continued short-term price momentum for the stock [1][2]. Estimate Revisions - The rising trend in estimate revisions reflects growing analyst optimism regarding Dentsply's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Dentsply is projected to earn $0.50 per share, representing a year-over-year increase of +2.04%. Over the last 30 days, eight estimates have been revised upward, resulting in a 9.41% increase in the Zacks Consensus Estimate [6]. - For the full year, the expected earnings per share is $1.89, indicating a +13.17% change from the previous year. Nine estimates have moved higher in the past month, contributing to a 5.06% increase in the consensus estimate [7][8]. Zacks Rank - Dentsply has achieved a Zacks Rank of 2 (Buy), indicating favorable estimate revisions. Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9]. - The Zacks Rank system has a strong track record, with Zacks 1 Ranked stocks generating an average annual return of +25% since 2008 [3]. Stock Performance - Dentsply shares have increased by 17.2% over the past four weeks, suggesting that investors are responding positively to the company's impressive estimate revisions [10].

At a time when volatility is striking every second day, investors can rely on value investing rather than other options like growth or momentum. As soon as other investors start selling their stocks at a cheaper rate in times of market uncertainty, value investors take this as an opportunity to pick good stocks at a discounted price.Several stocks that have surged significantly in the recent past have shown the overwhelming success of this pure-play investment strategy. Here, we discuss four such stocks - U ...

CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a g ...

Core Viewpoint - The analysis compares Align Technology (ALGN) and Merit Medical (MMSI) to determine which stock is more attractive to value investors, highlighting ALGN's stronger earnings outlook and better valuation metrics [1][3]. Valuation Metrics - ALGN has a forward P/E ratio of 16.57, while MMSI has a forward P/E of 28.45, indicating that ALGN is potentially undervalued compared to MMSI [5]. - The PEG ratio for ALGN is 1.48, suggesting a favorable earnings growth outlook, whereas MMSI's PEG ratio is 2.77, indicating a less attractive growth relative to its price [5]. - ALGN's P/B ratio stands at 3.30, compared to MMSI's P/B of 3.95, further supporting ALGN's valuation advantage [6]. Earnings Outlook - ALGN is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, suggesting it is a superior value option compared to MMSI [7].

BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET.A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/. ABOUT ENVISTA HOLDINGS CORPORATIONEnvista is a global family of more ...

Group 1 - atai Life Sciences N.V. (ATAI) is outperforming its peers in the Medical sector with a year-to-date return of approximately 43.6%, while the average return for Medical companies is -6.3% [4] - The Zacks Rank for atai Life Sciences N.V. is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - The Zacks Consensus Estimate for ATAI's full-year earnings has increased by 0.8% over the past quarter, reflecting improved analyst sentiment [4] Group 2 - atai Life Sciences N.V. is part of the Medical - Outpatient and Home Healthcare industry, which ranks 84 in the Zacks Industry Rank, and this industry has an average year-to-date return of 3.7% [6] - Cardinal Health (CAH), another stock in the Medical sector, has a year-to-date return of 29.6% and also holds a Zacks Rank of 2 (Buy) [5] - The Medical - Dental Supplies industry, to which Cardinal Health belongs, is currently ranked 42 and has experienced a year-to-date decline of -1% [7]

Core Viewpoint - Mobile-health Network Solutions (MNDR) has announced a new tele-dentistry service that utilizes AI-enabled dental scans, aimed at improving dental care accessibility in Southeast Asia, particularly for patients who do not regularly visit dentists [1][2][6]. Company Overview - MNDR is a leading MedTech innovator ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies and is the first telehealth provider from the Asia-Pacific region to be listed in the US [9]. Service Details - The new tele-dentistry service will allow patients to perform AI-enhanced dental scans at home using the MaNaDr telemedicine app, with expert-reviewed reports delivered within 24 hours [1][3]. - Patients can purchase a tele-dentistry package through the app, capture intraoral images with their smartphones, and receive detailed AI-generated reports highlighting potential dental issues [3][4]. - The service will launch in Singapore in summer 2025, with plans for expansion to Malaysia, Indonesia, and the Philippines by mid-2026 [5]. Market Need - The service targets the significant population in Southeast Asia that does not visit a dentist at least once a year, potentially at higher risk for dental conditions [6][7]. - According to the World Health Organization, oral diseases affect nearly 3.7 billion people globally, with untreated dental caries being the most common health condition [7]. Revenue Model - MNDR will earn an appointment booking fee and platform usage fee for each tele-dentistry session conducted through the MaNaDr app [5].

PALM BEACH GARDENS, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming Stifel 2025 Jaws & Paws Conference. Management will be presenting on Wednesday, May 28, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com. About ZimVieZimVie is a global lif ...